What's Hot
View all perspectives
Richard Conway RichardPAConway
2 years ago
Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD
Patricia Harkins DrTrishHarkins
2 years ago
Sphygmomanometer for fibromyalgia detection in rheum OPD
🔥⬆️local pain during BP testing strongly indicates presence of FMS
✅useful, easily applicable and practical screening tool
Abst#1225 #ACR22 @RheumNow
Bella Mehta bella_mehta
2 years ago
#FMF 2350 pts = 40% with arthritis
- Colchicine resistance in 20%
- M694V mutation carrier rate high (mutant MEFV gene)
- FMF pts with arthritis have a more severe disease course
- incidence of spondyloarthropathy was increased in FMF
#ACR22 @RheumNow abst#1830 https://t.co/uiLhjK0UjY
Richard Conway RichardPAConway
2 years ago
Rohmer @TerrierBen et al. 196 cases of PAN from France. 28% assoc another condition - MDS and cancer mainly. Relapse in 39% - assoc age>65, GI, skin necrosis. Death assoc age>65, AKI, secondary PAN, necrotic purpura. @RheumNow #ACR22 Abstr#2232 https://t.co/fyJY9O3Gm7
Dr. John Cush RheumNow
2 years ago
Tonight! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan
@RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22
https://t.co/j13W4GM56w https://t.co/fgDwPVdskC
Dr. John Cush RheumNow
2 years ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.
Richard Conway RichardPAConway
2 years ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer
- % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%)
- HR (high vs low) 0.98 (95% CI 0.36-2.61)
- No significant difference in risk of serious infxn
@RheumNow #ACR22 https://t.co/7Lfpf7PERu
Catherine Sims, MD DrCassySims
2 years ago
Which patients with IIM are high risk for #cancer?
Abstract #0002 #ACR22 @RheumNow #ACRBest
📍Dermatomyositis
📍Anti-TIF-gamma, anti-NXP2
📍Age > 40y at dz onset
📍Dysphagia
📍Cutaneous necrosis
📍Persistent high dz despite immunosuppressive tx
David Liew drdavidliew
2 years ago
Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?
TARGET study
n=159 using PET/CT surrogate (endpoint responsiveness👀)
- either led to benefit
- both equally good
- benefit *not* linked to change in DAS28
A direct CV effect of RA Rx?
ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
Dr. Antoni Chan synovialjoints
2 years ago
Vaccination +/- prior Covid-19, and with either mRNA or vectored DNA vaccines were not associated with AIRD flares. Negative association 21-days after 1st Covid-19 vaccination and no association after 2nd or 3rd doses. Nakafero G Abs#2194 https://t.co/vA8cMNQGkr #ACR22 @RheumNow https://t.co/SZnXejnmYt
Richard Conway RichardPAConway
2 years ago
Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk
Eric Dein ericdeinmd
2 years ago
Thieves Market #ACR22
Ulcerative palatal lesions, non-spec bx
+ANA 1:320 w other neg Abs
Empiric steroids for presumed vasculitis
New cavitary lung lesion. Pathology showed vasculitis
Dacrocystitis w lobulated paranasal mass
Dx: Extra nodal NK/T-cell lymphoma
Fatal case
@RheumNow https://t.co/TlDy9GfW7N
Poster Hall